Pure Bioscience Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pure Bioscience Inc 's ROA in the third quarter of 2026?
Pure Bioscience Inc recorded a cumulative net loss of $-2 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -181.48%.

However, within the Basic Materials sector 264 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Apr 30 2026 quarter, so far to 4461, from total ROA ranking in the second quarter of 2026 at 5180.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Apr 30 2026) III. Quarter	(Jan 31 2026) II. Quarter	(Oct 31 2025) I. Quarter	(Jul 31 2025) IV. Quarter	(Apr 30 2025) III. Quarter
Y / Y Total Assets Change	47.4 %	18.48 %	18.72 %	18.48 %	6.23 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-2	-2	-2	-2	-3
Return On Assets (TTM)	-181.48 %	-198.3 %	-207.34 %	-239.48 %	-293.91 %
PURE's Total Ranking	# 4461	# 5180	# 4608	# 4724	# 4834
Total Assets (TTM) in million	2	1	1	1	1
Seq. Total Assets Change	47.26 %	-10.79 %	12.1 %	0.09 %	18.37 %
Seq. Net Income Change	-	-	-	-	-

PURE's 5 Years Annual ROA >> Back to PURE Management Effectiveness >> Compare PURE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 65
Sector	# 265
Overall	# 4414

Return On Assets Statistics
High	Average	Low
20.69 %	-198.95 %	-573.76 %
(Oct 31 2020)		(Jul 31 2014)

Financial Statements
Pure Bioscience Inc 's Assets	$ 2 million	PURE's Balance sheet
Pure Bioscience Inc 's Income	$ -1 million	Quarterly PURE's Income Statement
PURE's Income by Division		See PURE's Income by Division

Annual Return On Assets	(Jul 31 2025) FY 2025	(Jul 31 2024) FY 2024	(Jul 31 2023) FY 2023	(Jul 31 2022) FY 2022	(Jul 31 2021) FY 2021
Y / Y Total Assets Change	18.48 %	-53 %	-58.32 %	5.95 %	-31.95 %
Total Assets in million	1	1	2	5	4
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-2	-3	-4	-3	-2
Annual Return On Assets	-226.75 %	-375.14 %	-208.47 %	-76.57 %	-53.89 %

PURE's 5 Years Annual ROA >> Back to PURE Management Effectiveness >> Compare PURE ROA to its Competitors

More Return On Assets Ratios
PURE's' Return on Assets at Yahoo Finance
Chemical Manufacturing Industry Return On Assets Trends and Statistics
Basic Materials Sector Roa Statistics
Roa Trends for overall market
PURE's Roa Ratio versus Chemical Manufacturing Industry, Basic Materials Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PURE's Competitors
Subscribers only: Roa for Pure Bioscience Inc 's Suppliers
Subscribers only: Return On Assets for PURE's Customers

You may also want to know
PURE's Roi	PURE's Inventory Turnover Ratio	PURE's Growth Rates	PURE's Dividend Comparisons
	PURE's Profitability Ratios	PURE's Asset Turnover Ratio	PURE's Dividend Growth
PURE's Roe	PURE's Valuation Ratios	PURE's Financial Strength Ratios	PURE's Dividend Payout Ratio

Companies with similar Return On Assets at Apr 30 2026, within Basic Materials Sector

ROA

Date modified: 2026-09-26T06:53:12+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.